Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-4571 in Healthy, Obese, and Type 2 Diabetes Participants
NCT06562907Phase 1Recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GS-4571 in obesity and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Gilead Sciences. Primary endpoints: Single-Dose PK Parameter AUCinf of GS-4571, Single-Dose PK Parameter Cmax of GS-4571 and 4 more. Started Aug 2024; status: recruiting.
02
Drugs
GS-4571
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06562907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562907.